A novel genes-based signature with prognostic value and predictive ability to select patients responsive to Atezolizumab treatment in bladder cancer: an analysis on data from real-world studies.

{"sci_version": "1.2", "schema": "https://corpus.bntrg.co.uk/sci/1.0/sci.schema.json", "id": "pmid:37701107", "kind": "science-record", "revision": 4, "content_hash": "sha256:22b1882294751640bf6c1c513e5cb77f871771b005ec3e6591f0e72c8ed381dd", "created_at": "2026-11-01T19:02:31Z", "updated_at": "2026-11-01T22:52:42Z", "generator": {"name": "corpus-assay-engine", "run_id": "reading-sci-2026-11-01"}, "paper": {"state": "complete", "title": "A novel genes-based signature with prognostic value and predictive ability to select patients responsive to Atezolizumab treatment in bladder cancer: an analysis on data from real-world studies.", "doi": "10.21037/tcr-23-220", "pmid": "37701107", "authors": ["Chunlei Zhang", "Yindong Kang", "Pengcheng Miao", "Dehui Chang"], "journal": "Translational cancer research", "year": 2023, "abstract": "Background: There is a lack of molecular markers that effectively predict response to treatment with immune checkpoint inhibitors in patients with uroepithelial bladder carcinoma. The purpose of this study was to explore molecular markers that effectively predict the efficacy of Atezolizumab in the treatment of uroepithelial bladder carcinoma based on real-world clinical trial data.\nMethods: Gene expression and clinical information of two groups of patients in two datasets, IMvigor210 and GSE176307, who were treated effectively and ineffectively with the programmed cell death 1 ligand 1 (PD-L1) inhibitor Atezolizumab, were obtained. Bioinformatic methods were used to screen out differentially expressed genes and detect the correlation between their expression and immune-related indicators. Subsequently, we assessed the ability of differentially expressed genes to predict the therapeutic response and prognosis of bladder cancer patients following Atezolizumab treatment.\nResults: A total of 2 differentially expressed genes, CXC motif chemokine ligand 9 (CXCL9) and CXC motif chemokine ligand 10 (CXCL10) [all P<0.05, log|fold change (FC)| >1], which were co-upregulated, were screened as study targets. In The Cancer Genome Atlas (TCGA) database, CXCL9/10 mRNA expression was positively correlated with both PD-L1 and tumor mutation burden (TMB) (all P<0.05). In the IMvigor210 dataset, the area under the receiver operating characteristic (ROC) curve for CXCL9, CXCL10 and PD-L1 mRNA expression to predict response to treatment with Atezolizumab were 0.645, 0.636 and 0.566, respectively; And CXCL9/10 mRNA was effective in predicting overall survival in patients receiving treatment (all P<0.05). In the GSE176307 dataset, the area under the ROC curve for CXCL9, CXCL10 and PD-L1 mRNA expression to predict response to treatment with Atezolizumab were 0.829, 0.829 and 0.765, respectively; And CXCL9/10 mRNA was not effective in predicting overall survival in patients receiving treatment (all P>0.05).\nConclusions: The mRNA expression levels of CXCL9/10 have the potential to serve as a molecular marker for predicting the therapeutic response and overall survival outcomes of bladder cancer patients treated with Atezolizumab.", "claims": [{"id": "claim-method", "statement": "Differences in gene expression between groups were analyzed using the Mann-Whitney U test. Spearman’s correlation coefficient was used to respond to gene expression. Log-rank test was used for prognostic analysis of KM curves.", "kind": "methodological", "target": null, "evidence": [{"asset": "source:pmid:37701107", "locator": "sections[6] \"Statistical analysis\" paragraph 2", "quote": "Differences in gene expression between groups were analyzed using the Mann-Whitney U test. Spearman’s correlation coefficient was used to respond to gene expression. Log-rank test was used for prognostic analysis of KM curves."}], "state": "complete"}, {"id": "claim-data-access", "statement": "The genetic sequencing results and clinical information of bladder cancer patients treated with Atezolizumab in the IMvigor210 (4) and GSE176307 (5) datasets were selected and divided into response and non-response groups according to treatment outcome of partial remission (PR), complete remission (CR), or disease progression (PD) and disease stabilization (SD).", "kind": "methodological", "target": null, "evidence": [{"asset": "source:pmid:37701107", "locator": "sections[4] \"Data sources\" paragraph 2", "quote": "The genetic sequencing results and clinical information of bladder cancer patients treated with Atezolizumab in the IMvigor210 (4) and GSE176307 (5) datasets were selected and divided into response and non-response groups according to treatment outcome of partial remission (PR), complete remission (CR), or disease progression (PD) and disease stabilization (SD)."}], "state": "complete"}, {"id": "claim-target-result", "statement": "In the IMvigor210 dataset, the area under the receiver operating characteristic (ROC) curve for CXCL9, CXCL10 and PD-L1 mRNA expression to predict response to treatment with Atezolizumab were 0.645, 0.636 and 0.566, respectively; And CXCL9/10 mRNA was effective in predicting overall survival in patients receiving treatment (all P<0.05).", "kind": "quantitative", "target": {"value": 0.05, "unit": "p-value", "tolerance": null, "source": "In the IMvigor210 dataset, the area under the receiver operating characteristic (ROC) curve for CXCL9, CXCL10 and PD-L1 mRNA expression to predict response to treatment with Atezolizumab were 0.645, 0.636 and 0.566, respectively; And CXCL9/10 mRNA was effective in predicting overall survival in patients receiving treatment (all P<0.05)."}, "evidence": [{"asset": "source:pmid:37701107", "locator": "sections[0] \"Abstract\" paragraph 3", "quote": "In the IMvigor210 dataset, the area under the receiver operating characteristic (ROC) curve for CXCL9, CXCL10 and PD-L1 mRNA expression to predict response to treatment with Atezolizumab were 0.645, 0.636 and 0.566, respectively; And CXCL9/10 mRNA was effective in predicting overall survival in patients receiving treatment (all P<0.05)."}], "state": "complete"}], "gaps": []}, "experiment": {"state": "partial", "objective": "In the IMvigor210 dataset, the area under the receiver operating characteristic (ROC) curve for CXCL9, CXCL10 and PD-L1 mRNA expression to predict response to treatment with Atezolizumab were 0.645, 0.636 and 0.566, respectively; And CXCL9/10 mRNA was effective in predicting overall survival in patients receiving treatment (all P<0.05).", "steps": [{"id": "read_published_estimate", "order": 1, "name": "Read the published estimate from the source", "kind": "other", "state": "complete", "blocked_on": null, "description": "The claim, method and evidence span published with the source article.", "duration_hours": null, "parameters": {}, "inputs": ["source:pmid:37701107"], "outputs": ["the published estimate and its evidence"], "instruments": [], "reagents": []}, {"id": "obtain_source_data", "order": 2, "name": "Obtain the source data from the named repository", "kind": "data-preparation", "state": "complete", "blocked_on": null, "description": "The GEO series accession resolves and its sample accessions are listed. This lane did not download the dataset or read its licence.", "duration_hours": null, "parameters": {}, "inputs": ["data:geo:GSE176307"], "outputs": ["the source data with its repository provenance"], "instruments": [], "reagents": []}, {"id": "run_analysis", "order": 3, "name": "Run the published analysis", "kind": "analysis", "state": "blocked", "blocked_on": "method:group_comparison_mann_whitney", "description": "Apply the paper's statistical method to the resolved series and compare the result with the published target.", "duration_hours": null, "parameters": {}, "inputs": ["data:geo:GSE176307"], "outputs": ["the replicated result and its comparison"], "instruments": [], "reagents": []}], "materials": [], "instruments": [], "reagents": [], "conditions": {}, "gaps": ["step:run_analysis blocked on method:group_comparison_mann_whitney"]}, "data": {"state": "partial", "assets": [{"id": "source:pmid:37701107", "role": "manuscript", "format": "xml", "media_type": "application/xml", "uri": "https://doi.org/10.21037/tcr-23-220", "sha256": "sha256:30747071f777e601cfe1af9eec18bc3c3ca1e6d289d85005e16e914703528aeb", "bytes": 25832, "access": "open", "state": "resolved", "reader": null, "reader_status": "reader_required", "identifier": "10.21037/tcr-23-220", "version": null, "note": "Full article fetched from PMC; the checksum covers the rendered section body, not the original XML bytes.", "structure": {"pmcid": "PMC10493780", "source": "europe_pmc_fulltext", "coverage": "whole_body", "text_hash_scope": "rendered_section_body"}}, {"id": "data:geo:GSE176307", "role": "raw", "format": "geo-series", "media_type": "application/vnd.ncbi.geo-series+json", "uri": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE176307", "sha256": null, "bytes": null, "access": "open", "state": "resolved", "reader": null, "reader_status": "reader_required", "identifier": "GSE176307", "version": null, "note": "The genetic sequencing results and clinical information of bladder cancer patients treated with Atezolizumab in the IMvigor210 (4) and GSE176307 (5) datasets were selected and divided into response and non-response groups according to treatment outcome of partial remission (PR), complete remission (CR), or disease progression (PD) and disease stabilization (SD).", "structure": {"repository": "GEO", "access_route": "GEO accession URL", "access_statement_verbatim": "The genetic sequencing results and clinical information of bladder cancer patients treated with Atezolizumab in the IMvigor210 (4) and GSE176307 (5) datasets were selected and divided into response and non-response groups according to treatment outcome of partial remission (PR), complete remission (CR), or disease progression (PD) and disease stabilization (SD).", "access_statement_kind": "repository_route_statement", "sample_accessions": ["GSM5362464", "GSM5362465", "GSM5362466", "GSM5362467", "GSM5362468", "GSM5362469", "GSM5362470", "GSM5362471", "GSM5362472", "GSM5362473", "GSM5362474", "GSM5362475", "GSM5362476", "GSM5362477", "GSM5362478", "GSM5362479", "GSM5362480", "GSM5362481", "GSM5362482", "GSM5362483", "GSM5362484", "GSM5362485", "GSM5362486", "GSM5362487", "GSM5362488", "GSM5362489", "GSM5362490", "GSM5362491", "GSM5362492", "GSM5362493", "GSM5362494", "GSM5362495", "GSM5362496", "GSM5362497", "GSM5362498", "GSM5362499", "GSM5362500", "GSM5362501", "GSM5362502", "GSM5362503", "GSM5362504", "GSM5362505", "GSM5362506", "GSM5362507", "GSM5362508", "GSM5362509", "GSM5362510", "GSM5362511", "GSM5362512", "GSM5362513", "GSM5362514", "GSM5362515", "GSM5362516", "GSM5362517", "GSM5362518", "GSM5362519", "GSM5362520", "GSM5362521", "GSM5362522", "GSM5362523", "GSM5362524", "GSM5362525", "GSM5362526", "GSM5362527", "GSM5362528", "GSM5362529", "GSM5362530", "GSM5362531", "GSM5362532", "GSM5362533", "GSM5362534", "GSM5362535", "GSM5362536", "GSM5362537", "GSM5362538", "GSM5362539", "GSM5362540", "GSM5362541", "GSM5362542", "GSM5362543", "GSM5362544", "GSM5362545", "GSM5362546", "GSM5362547", "GSM5362548", "GSM5362549", "GSM5362550", "GSM5362551", "GSM5362552", "GSM5362553"], "sample_count": 90, "group_sizes": null, "group_sizes_basis": null, "platform": "24014", "taxon": "Homo sapiens", "title": "Fibroblast Growth Factor Receptor 3 Alterations and Response to Immune Checkpoint Inhibition in Metastatic Urothelial Cancer: A Real World Experience", "resolution_checked_at": "2026-11-01T17:30:42Z", "resolution_check": "identifier_resolution_only_no_download_no_licence_read", "downloaded": false, "licence_read": false}}], "gaps": ["asset:data:geo:GSE176307 not downloaded", "asset:data:geo:GSE176307 licence not read"]}, "analysis": {"state": "partial", "methods": [{"id": "method-1", "family": "group_comparison", "specific": "mann_whitney", "label": "Group comparison", "dsl_operations": [], "missing_operations": ["group_comparison_mann_whitney"], "expressible": false, "parameters": {}, "data_shapes": ["two_or_more_groups_continuous"], "evidence": {"score": 1.0, "band": "verbatim", "quote": "Differences in gene expression between groups were analyzed using the Mann-Whitney U test. Spearman’s correlation coefficient was used to respond to gene expression. Log-rank test was used for prognostic analysis of KM curves."}}, {"id": "method-2", "family": "survival_analysis", "specific": "kaplan_meier", "label": "Survival analysis", "dsl_operations": ["survival_km"], "missing_operations": [], "expressible": true, "parameters": {}, "data_shapes": ["time_to_event_with_censoring"], "evidence": {"score": 0.8, "band": "high", "quote": "KM"}}, {"id": "method-3", "family": "survival_analysis", "specific": "log_rank_test", "label": "Survival analysis", "dsl_operations": ["logrank_test"], "missing_operations": [], "expressible": true, "parameters": {}, "data_shapes": ["time_to_event_with_censoring"], "evidence": {"score": 0.8, "band": "high", "quote": "Log-rank"}}, {"id": "method-4", "family": "diagnostic_evaluation", "specific": "roc", "label": "Diagnostic test evaluation", "dsl_operations": ["confusion_counts", "roc_curve", "sensitivity_specificity", "solve_confusion_matrix", "classification_metrics", "published_precision_envelope"], "missing_operations": [], "expressible": true, "parameters": {}, "data_shapes": ["reference_standard_and_test"], "evidence": {"score": 0.7, "band": "medium", "quote": "ROC curve"}}], "targets": [{"id": "target-published-estimate", "claim_id": "claim-target-result", "operation": "classification_metrics", "expected_value": 0.05, "unit": "p-value", "tolerance": null, "state": "complete", "note": "The threshold the paper applied to its own result, as the paper states it. A run that reproduces the effect is judged against this threshold."}], "gaps": ["method.group_comparison_mann_whitney"]}, "capability": {"state": "complete", "requirements": [{"capability_id": "capability:computational_analysis", "label": "Computational analysis platform", "assay_families": ["meta_analysis", "machine_learning", "survival_analysis", "statistical_regression", "pca", "molecular_docking", "network_analysis", "differential_expression", "gwas"], "availability_state": "owned", "tier_unlocked": "R1", "candidate": "Automated Assays Laravel application and simulated adapters"}], "gaps": []}, "readiness": {"state": "complete", "tier": "R1", "blocking_axis": "none", "blocked_on": "nothing:replicable_now", "axes": {"method": {"tier": "R1", "expressible": false, "required_operations": [], "missing_operations": ["group_comparison_mann_whitney"], "basis": "The paper names the method it used and the corpus's method extractor maps it onto the DSL catalogue: mann_whitney."}, "capability": {"tier": "R1", "capability_id": "capability:computational_analysis", "availability_state": "owned", "basis": "The computational analysis is owned. The physical bench the paper used is not, so a physical validation cannot be run here."}, "data": {"tier": "R1", "reachable": true, "accessions": ["GSE176307"], "resolved_accessions": ["GSE176307"], "statements": ["The genetic sequencing results and clinical information of bladder cancer patients treated with Atezolizumab in the IMvigor210 (4) and GSE176307 (5) datasets were selected and divided into response and non-response groups according to treatment outcome of partial remission (PR), complete remission (CR), or disease progression (PD) and disease stabilization (SD)."], "basis": "The paper names GSE176307 in GSE176307 dataset and the accession resolves in the repository. No dataset was downloaded and no licence was read."}}, "can_run": {"dsl_operations": [], "assets": ["source:pmid:37701107", "data:geo:GSE176307"], "steps": []}, "must_build": {"dsl_operations": [{"operation": "group_comparison_mann_whitney", "unlocks_papers": null, "priority": null}], "converters": [], "readers": [], "capabilities": [], "data_gaps": ["data:geo:GSE176307"]}, "gaps": []}, "review": {"state": "partial", "machine_critique": {"kind": "extraction_review", "reader": {"model": "MiniMax-M3.1-Flash", "provider": "minimax", "provider_family": "minimax", "read_at": "2026-11-01T18:53:21Z", "independence": "single_reader"}, "evidence_check": {"method": "verbatim", "availability": null}, "calls": 5, "usage": {"prompt_tokens": 8263, "completion_tokens": 2505, "cached_tokens": 128}}, "human_critique": null, "stages": [{"id": "extraction", "state": "complete", "reader": "MiniMax-M3.1-Flash", "provider": "minimax"}], "gaps": ["review.independent_reader", "review.machine_critique", "review.human_critique"]}, "execution": {"state": "absent", "status": "not_run", "mode": null, "runs": [], "gaps": ["execution.not_run"]}, "provenance": {"entities": [{"id": "pmid:37701107", "type": "paper", "label": "pmid:37701107"}, {"id": "source:pmid:37701107", "type": "manuscript", "label": "PMID 37701107 full text"}, {"id": "data:geo:GSE176307", "type": "dataset", "label": "GEO GSE176307"}], "activities": [{"id": "activity-reading-sci-2026-11-01", "type": "classification", "used": [{"id": "pmid:37701107", "type": "paper", "label": "pmid:37701107"}, {"id": "source:pmid:37701107", "type": "manuscript", "label": "PMID 37701107 full text"}, {"id": "data:geo:GSE176307", "type": "dataset", "label": "GEO GSE176307"}], "agent": "agent:corpus-assay-engine"}, {"id": "activity-read-37701107", "type": "extraction", "used": ["source:pmid:37701107"], "agent": "agent:minimax-reader"}, {"id": "activity-resolve-GSE176307", "type": "accession_resolution", "used": ["data:geo:GSE176307"], "agent": "agent:corpus-assay-engine"}], "agents": [{"id": "agent:corpus-assay-engine", "type": "software", "label": "Corpus assay engine"}, {"id": "agent:minimax-reader", "type": "software", "label": "MiniMax literature reader"}], "source_run_id": "reading-sci-2026-11-01", "dsl_catalogue_fingerprint": "343fb30756ba6ec3", "capability_table_fingerprint": "2cb3e42f047d2ecf", "snapshot_id": "ba34b49490d9bfaf"}, "lineage": {"parent_id": "pmid:37701107", "parent_hash": "sha256:4e2baaa2bdc3caa86aaadf407c348eb8f5dceec7b307a16a057325e9c7a5564b", "fork_of": null, "generation": 3}, "gaps": ["asset:data:geo:GSE176307 licence not read", "asset:data:geo:GSE176307 not downloaded", "execution.not_run", "method.group_comparison_mann_whitney", "review.human_critique", "review.independent_reader", "review.machine_critique", "step:run_analysis blocked on method:group_comparison_mann_whitney"], "assays": [{"role": "analysis", "definition_id": "group_comparison", "definition_version": "f2132e96ae6c7a4e", "definition_digest": null, "required_operations": [], "support_state": "partial", "source_hashes": {"dsl_catalogue": "f2132e96ae6c7a4e"}, "confidence": 1.0, "evidence": ["Differences in gene expression between groups were analyzed using the Mann-Whitney U test. Spearman’s correlation coefficient was used to respond to gene expression. Log-rank test was used for prognostic analysis of KM curves."], "order_basis": "analysis_only", "id": "assay:1"}]}